BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 9, 2018
View Archived Issues
Stemline Therapeutics initiates rolling BLA submission for SL-401
Read More
Iontas to collaborate with Igem to identify novel IgE antibodies
Read More
Sapience Therapeutics and University of Bath enter oncology drug discovery collaboration
Read More
Biomarker of EMT linked to progression and prognosis in esophageal adenocarcinoma
Read More
Researchers present phase I data on hESC-RPE patch in age-related macular degeneration
Read More
Guangzhou Bainifu Biotech patents chimeric antigen receptors targeting CD133
Read More
Novel phospholipase A2 inhibitors discovered at Haplogen
Read More
Sichuan Haisco Pharmaceutical divulges new CACNA2D1 ligands
Read More
ImmunoPrecise Antibodies completes acquisition of ModiQuest Research
Read More
EyeGate completes enrollment in phase III study of EGP-437
Read More
PIAS1 inhibition may enhance radiotherapy for breast cancer
Read More
FunPep enters option agreement on antibody-inducing peptides with Sumitomo Dainippon Pharma
Read More
Pivotal phase III ECHO-301/KEYNOTE-252 study of epacadostat does not meet primary endpoint
Read More
Protocadherin-23 tied to adverse prognostic factors in breast cancer
Read More
FDA accepts NDA for duvelisib
Read More
FDA grants approval for Rubraca as maintenance treatment of recurrent ovarian cancer
Read More
Bayer enrolling participants in phase I trial of BAY-2402234
Read More
DGKB biomarker tied to antipsychotic therapy-induced weight gain
Read More
Enrollment ongoing in phase I trial of NGM-120
Read More
Recordati acquires rights to Cystagon
Read More
Phase II ATOMIK study of serlopitant does not meet primary or key secondary efficacy endpoints
Read More
Phase II study of FP-101 recruiting participants
Read More
Servier enters agreement with and Scandicure to conduct research in the field of metabolic diseases
Read More
AH10-7 is an improved immunotherapeutic activator of invariant natural killer T cells
Read More
Takara Bio and Otsuka to codevelop NY-ESO-1 siTCR and CD19 CAR gene therapy
Read More
FDA approves sNDA for Exparel as a nerve block to produce regional analgesia
Read More